SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Not only is Siga's share price up, but trading volumes are through the roof.

Could This Be the Next Big Meme Stock?

Moderna

Shares of the company have jumped more than 60% in just the past month.

Could SIGA Technologies Become the Next Moderna?

Applied DNA Sciences

Chimerix

Geovax Labs

iShares Genomics Immunology and Healthcare ETF

Tonix Pharmaceuticals Hld

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Ayala Pharmaceuticals

Blue Water Vaccines

E-Home Household Service Holdings Ltd

Ameri Holdings

Koss

Stronghold Digital Mining

The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic about.

7 Short-Squeeze Stocks to Put on Your Must-Watch List

Tarena International

In a year where investing in stocks was more challenging than usual, finding winning stocks has been tough.

These three stocks recorded gains of over 200% year-to-date

- IV TPOXX is an Important Option for Those Unable to Swallow –

SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®

There's a lot going on with Siga Technologies (NASDAQ: SIGA ) stock lately. First of all, Siga released its second-quarter 2022 financial results.

Siga Technologies Stock May Be a Runner Now, But It Still Is a Good Value

The monkeypox outbreak has sent the drugmaker's stock up more than 200% this year, though its antiviral remains hard to access in the U.S.

SIGA Says It Plans to Seek FDA Approval of Monkeypox Drug

The monkeypox outbreak has sent the drugmaker's stock up more than 200% this year, though the company's monkeypox antiviral remains hard to access in the U.S.

SIGA to Seek FDA Approval of Monkeypox Drug When Data Is Available

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Phillip Gomez - CEO & Director Dennis Hruby - EVP & Chief Scientific Officer Daniel Luckshire - EVP, CFO & Secretary Conference Call Participants Soo Romanoff - Edison Group Peter Imber - North Point Partners Operator Welcome to the SIGA business update call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA Technologies, Inc. (SIGA) CEO Phillip Gomez on Q2 2022 Results - Earnings Call Transcript

Is It Too Late to Buy SIGA Technologies Stock?

- Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX® Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales –

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022

Aethlon Medical

Chembio Diagnostics

NanoViricides

10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Monkeypox Stocks To Watch Right Now

Quest Diagnostics

Labcorp Holdings Inc

A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.

These 3 Companies Are Taking on Monkeypox

The medicine Siga Technologies developed to combat biowarfare is now being used in the ongoing viral outbreak, and Siga stock has exploded.

How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak

Emergent BioSolutions

Should investors be watching these monkeypox stocks right now?

MonkeyPox Stocks To Buy Right Now? 3 To Know

After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpox and/or monkeypox, further de-risking the equity story.

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

Virax Biolabs Group Ltd

Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency orders related to monkeypox. Several related names rallied in pre-market trading today and are still up since the market opened this morning.

Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears

Shares of SIGA Technologies (NASDAQ: SIGA ) closed lower by more than 20% following the release of a Food and Drug Administration (FDA) update. That update stated that SIGA's TPOXX, or tecovirimat, antiviral medication has not yet demonstrated any efficacy against monkeypox.

Why Is SIGA Technologies (SIGA) Stock Plunging 23% Today?

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 4th, 2022. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dennis Hruby, Chief Scientific Officer.

SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results

SIGA Technologies (NASDAQ: SIGA ) stock is seeing double-digit gains once again, as investors grow increasingly bullish on biotech firms with vaccines combating monkeypox. This enthusiasm started yesterday, after the World Health Organization (WHO) declared the monkeypox outbreak a global health emergency.

SIGA Stock Gains Another 11% on Monkeypox Virus Concerns

SigaTech saw its IBD SmartSelect Composite Rating jump to 97 Tuesday, up from 94 the day before. The post SigaTech Earns Membership In 95-Plus Composite Rating Club appeared first on Investor's Business Daily.

SigaTech Earns Membership In 95-Plus Composite Rating Club

The drugmaker's smallpox drug may play a key role in combatting the global outbreak of monkeypox.

Why Siga Technologies Stock Is Soaring Today

Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency appeared first on InvestorPlace.

Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency

It's not every day that SIGA stock trends in the financial media, but today vaccine stocks are in focus due to the spread of monkeypox. The post SIGA Stock Soars as WHO Declares Monkeypox Global Health Emergency appeared first on InvestorPlace.

News for SIGA Technologies Stock (SIGA)